BRIEF—Ichnos Sciences appoints new chief development officer

Ichnos Sciences has appointed Gabriela Gruia as chief development officer, overseeing asset development including regulatory, clinical, drug safety, and other functions.

Dr Gruia was previously senior vice president and head of regulatory affairs for Novartis Oncology.

She commented: "Ichnos has a portfolio of first-in-class and potentially best-in-class candidates that may help address a broad range of complex diseases. I look forward to working with the leadership team to advance our pipeline and further Ichnos' mission of providing breakthrough therapies that can extend and improve lives."

In 2019 Indian generics maker Glenmark Pharmaceuticals spun out its R&D unit into Ichnos Sciences, an independent, fully integrated biotech firm based in New Jersey, USA.